News for Viatris Inc Registered Shs

Seeking Alpha 3h

Gilead wins FDA approval for twice-yearly HIV PrEP therapy

Seeking Alpha 1d

How are generic drugmakers reacting to Trump’s push for domestic production?

Seeking Alpha 1d

Global pharma stocks down as Trump renews tariff threat

TipRanks 12d

Viatris (VTRS) Receives a New Rating from Goldman Sachs

Seeking Alpha 12d

Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space

Seeking Alpha 12d

Theravance and Viatris settle patent dispute with Eugia Pharma

TipRanks 13d

Viatris initiated with a Neutral at Goldman Sachs

TipRanks 14d

Viatris management to meet with Piper Sandler

Seeking Alpha 16d

Viatris sees positive top-line phase 3 results for night driving impairment asset

TipRanks 16d

Viatris announces ‘positive’ results from Phase 3 trial evaluating MR-142

TipRanks 22d

Bronstein, Gewirtz & Grossman announces class action lawsuit against Viatris

TipRanks 27d

Viatris (VTRS) Gets a Hold from Piper Sandler

TipRanks 28d

FTC renews Orange Book listing disputes

TipRanks 33d

VTRS Lawsuit Alert! Class Action Lawsuit Against Viatris Inc.

Seeking Alpha 36d

S&P 500 turns positive for 2025; here are its best and worst YTD performers

Seeking Alpha 38d

Notable healthcare headlines for the week: Viatris, Novavax and UnitedHealth in focus

Seeking Alpha 40d

SA analyst downgrades: VTRS, MRVL, MAR, NTR, CRSP, DB, VRSK, OCSL

TipRanks 41d

Viatris files automatic mixed securities shelf

Seeking Alpha 41d

Biggest stock movers Thursday: Crypto stocks, BYND, CLF, VTRS, G, and more

TipRanks 41d

Early notable gainers among liquid option names on May 8th

Seeking Alpha 41d

Viatris rises as Q1 beat comes with late-stage trial wins

Seeking Alpha 41d

Viatris hits main goals in Phase 3 trial for birth control patch

Seeking Alpha 41d

Viatris in charts: Generic sales drop 16% in Q1; revenue from Developed Markets falls 13%

Seeking Alpha 41d

Viatris rises as late-stage trials for non-opioid pain therapy succeed

Seeking Alpha 41d

Viatris Non-GAAP EPS of $0.50 beats by $0.01, revenue of $3.25B beats by $10M

Seeking Alpha 42d

Viatris Q1 Earnings Preview: Analysts expect profit to decline by about 27%

Seeking Alpha 42d

Viatris declares $0.12 dividend

Seeking Alpha 43d

Heron settles patent dispute with Viatris over antiemetic agents

Seeking Alpha 43d

Viatris pulls generic for Teva’s Trisenox in EU

Seeking Alpha 45d

Earnings week ahead: AMD, PLTR, F, DIS, SHOP, DKNG, AMC, LCID, GOLD, RIVN, and more

Seeking Alpha 45d

About 78% of the names that reported earnings this week delivered EPS wins: Earnings Scorecard

Seeking Alpha 46d

Healthcare sector flexes earnings muscle, but top-line cracks show

TipRanks 50d

Piper Sandler Sticks to Its Hold Rating for Viatris (VTRS)

Seeking Alpha 51d

Viatris on track to close seventh straight session of gains

TipRanks 51d

Early notable gainers among liquid option names on April 28th

TipRanks 58d

Viatris price target lowered to $8 from $10 at BofA

TipRanks 58d

Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Xtant Medical Holdings (XTNT) and Medtronic (MDT)

TipRanks 58d

Bank of America Securities Keeps Their Sell Rating on Viatris (VTRS)

TipRanks 58d

Viatris files Effexor supplemental new drug applications to Japan MHLW

TipRanks 65d

Viatris appoints Hemanth Varghese as chief strategy officer

Seeking Alpha 70d

Pharma, MedTech stocks bounce back as Trump pauses most tariffs

Seeking Alpha 70d

Bristol-Myers gets Pomalyst antitrust case dismissed

Seeking Alpha 72d

Viatris to pay up to $335M to settle opioid-related claims

TipRanks 72d

Viatris reaches nationwide settlement to resolve opioid-related claims

Seeking Alpha 77d

Pharmaceuticals excluded from tariffs announced by Trump

Seeking Alpha 78d

CVS, COR, among top S&P 500 healthcare gainers in Q1; WST and MRNA among losers

TipRanks 79d

Viatris put volume heavy and directionally bearish

Seeking Alpha 86d

Trump reiterates plan to impose tariffs on pharmaceuticals

TipRanks 96d

Concerns increase around adverse effects of benzodiazepines, WSJ says

TipRanks 103d

Viatris price target lowered to $13 from $15 at Jefferies

	
		OSZAR »